Products

Magellan manufactures mesenchymal stem cell products for the treatment of osteoarthritis.

Contact

Autologous stem cell treatments

Magellan’s autologous products use each patient’s own stem cells to treat their osteoarthritis.

A patient’s cells are harvested, expanded and undergo quality control to ensure the stem cells are viable, free of any contamination and are truly stem cells based on the international stem cell classifications.

More than 1500 people have been treated in these autologous stem cell trials for osteoarthritis, with the results published in scientific journals.

Donor stem cell treatment

Magellan has developed Zelestrocel, an off-the-shelf mesenchymal stem cell treatment for osteoarthritis.

Zelestrocel, an allogenic or donor product, has undergone Phase I/IIa trials and a Phase III trial is planned to commence in late 2026.

The early trials indicated the product is safe and has efficacy, also indicating that stem cells are “immune evasive”, i.e. don’t trigger an immune response.

Magellan believes Zelestrocel has the potential to defer the need for expensive joint replacement surgery for many osteoarthritis sufferers.

Stem cell trials

Magellan and our research collaboration partners at Melbourne Stem Cell Centre Research have undertaken or contributed to both autologous (patients’ own) and allogeneic (donor) stem cell research and trials. Magellan’s Zelestrocel allogeneic (donor) product has undergone Phase I/IIa trials, with the results published in Osteoarthritis and Cartilage Open. Links to Magellan’s published research are available on the Research page.

Magellan Stem Cells product Zelestrocel to date

Pre-clinical research

Phase I & II for Clinical Safety and primary efficacy

Phase III for Clinical Efficacy Trial – starting in 2026

Our product Zelestrocel has successfully completed Phase I/II clinical trials on the use of allogeneic (donor) off-the-shelf stem cell therapy for OA. The pivotal Phase III trial is planned to commence in 2026.

Magellan has secured a GMP licence from the Therapeutic Goods Administration (TGA).